Group 1 - The Hong Kong stock market continues to strengthen, with the Hang Seng Index breaking through new highs since 2022, closing up 0.54% [1] - The innovative drug sector is active, with the Hong Kong Stock Connect Innovative Drug ETF (520880) reaching a new high, trading volume increased by 47% [1] - Southwest Securities suggests focusing on innovative drugs and their industrial chain due to BD expansion, R&D progress, and policy support [2] Group 2 - Guojin Securities identifies innovative drugs as the current investment focus, particularly in the context of multinational corporations seeking BD collaborations for potential blockbuster drugs [3] - The market capitalization of biotechnology and medical technology in the Hong Kong pharmaceutical sector is 40%, compared to 24% in A-shares, indicating higher innovation content in Hong Kong stocks [3] - The top ten stocks in the Hang Seng Stock Connect Innovative Drug Index account for 75.85% of the index weight, with a year-to-date increase of 58.95%, outperforming other indices [5][6] Group 3 - Leading stocks include Lijuzhiyuan, which surged over 9% after successful clinical trial results, and other companies like Zai Lab and United Pharmaceuticals also saw significant gains [4] - The innovative drug sector is characterized by high initial investment and long profit cycles, with Hong Kong being more accommodating for loss-making companies to list [3][4]
“药”不能停！港股通创新药ETF（520880）放量上探3%，丽珠医药、康方生物齐刷新高